Skip to main content
Hit enter to search or ESC to close
Close Search
search
Menu
About Us
Impact company
Purposeful innovation coupled with a responsible company model can positively impact Global Health
Our people
Our strength: valuing and nurturing our team’s entrepreneurial spirit, expertise, and dedication
Leadership Team
Seasoned leaders unite to tackle global health challenges
Science
UZEDY®
Relapse prevention long-acting treatment for schizophrenia
R&D Pipeline
Advancing therapeutic care with precision Delivery
BEPO® technology
Our technology platform to develop long-acting treatments
Publications
Facilitate collaboration with our collection of scientific articles and presentations
Responsibility
Our commitments
Transforming global health with purposeful innovation
Code and policies
High standards for all company’s stakeholders
2024 ESG report
Social and environmental information about the company and its activities
Careers
Our vision & our values
See how our HR vision and values shape a dynamic workforce
Work environment & benefits
Explore the benefits and environment driving our team’s success
Join us
Embark on a career journey where your talents meet opportunity
News & events
Newsroom
Latest updates and announcements, the gateway to all press releases
Events
Earnings calls, conferences, General Meeting: live and replay
Investors
Overview
All information and news about Medincell stock
Reports & regulated information
Financial reports, operational updates, and shareholder information
General Meeting
All documents related to the Medincell Shareholders’ Meetings
Leadership team
Seasoned leaders unite to tackle global health challenges
Contact
EN
FR
search
General
Home
Investors
News
Uzedy
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
By
Medincell
November 4, 2024
January 16th, 2025
No Comments
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
November 4, 2024
Previous Post
25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
Next Post
Participation in Leading Investor Conferences
Close Menu
Home
About Us
Impact company
Our people
Leadership team
Science
UZEDY®
R&D Pipeline
BEPO® technology
Publications
Responsibility
Our commitments
Code and policies
2023 ESG Report
Careers
Our vision & our values
Work environment & benefits
Join us
News & events
News
Events
Investors
Overview
Regulated information
General Meeting
Leadership team
Contact
FR
